Chemist Peter Parker spent 18 years as a general partner at Ampersand Capital Partners before becoming CEO of the RNAi pharmaceutical company Cequent Pharmaceuticals, but he does not recommend life sciences investing as a career, given its competing demands and steep learning curve. "It took me 10 years to even feel confident in making investments and working with companies," Parker said. Most companies do not live up to expectations, and many fail, whether gradually or quickly, he said.

Full Story:

Related Summaries